Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 46,052

Document Document Title
WO/2018/186366A1
The present invention addresses the problem of providing a novel cyclin-dependent kinase 8 and/or 19 inhibitor that is useful as an anticancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor that c...  
WO/2018/185671A1
The present invention relates to nanofibers (1) comprising an outer membrane (2) and a core (3) wherein said outer membrane (2) is made of fibroin and said core (3) is a biocompatible and biodegradable polymer. The present invention furt...  
WO/2018/186480A1
The inventors of the present invention found that an HMGB1 peptide fragment having a specific amino acid sequence is effective at suppressing finger fusion and scarring of the digestive tract, and at prolonging survival in malnutrition- ...  
WO/2018/181987A1
Provided is an adsorbent for indole and derivatives thereof that selectively adsorbs indole and derivatives thereof (particularly indole). A copolymer synthesized by mixing structural units based on each monomer at an optimal ratio was d...  
WO/2018/181345A1
Provided is a compound which has an Nrf2-activating activity and is expected to be useful as a prophylactic or therapeutic agent for diseases associated with oxidative stress, particularly hepatitis (e.g., non-alcoholic steatohepatitis (...  
WO/2018/176330A1
Provided are microRNA from a rhodiola root and uses thereof in the prevention and/or the treatment of a fibroplasia medical sign and/or syndrome.  
WO/2018/181820A1
The present invention relates to a compound that can be effective for prevention and/or treatment of pulmonary hypertension, pulmonary fibrosis, fibrosis in the liver, kidney, skin, or heart, non-alcoholic steatohepatitis, diabetic nephr...  
WO/2018/171611A1
A 6-pyrazole-[1,2,4]triazolo[4,3-a]pyridine-3-amide derivative as represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, use thereof as a therapeutic agent, in particula...  
WO/2018/172380A1
The invention relates to a use of Copaifera oleoresin for producing a medicament for preventing and/or treating pathologies of the prostate, particularly benign prostatic hyperplasia and/or prostate cancer.  
WO/2018/171816A1
Disclosed in the present invention are a deuterated dipeptide boronic acid or an ester compound thereof, or a crystalline form, pharmaceutically acceptable hydrate or solvate thereof, the structure thereof being shown in formula (a), whe...  
WO/2018/171004A1
Provided are a class of compounds, which have an anti-platelet aggregation activity, of general formula I and a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition and use thereof. Th...  
WO/2018/168818A1
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them an...  
WO/2018/166494A1
The present disclosure relates to the use of a compound as shown in formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating diabetes mellitus, or the use of same in the...  
WO/2018/169055A1
It is known that foods containing a carbohydrate, e.g., starch, in a large amount generate acrylamide upon heating at high temperatures. Some documents state that acrylamide is formed by the Maillard reaction of an amino acid, e.g., aspa...  
WO/2018/168894A1
The present invention relates to a medicine for the treatment of diseases in which Nav1.7 participates, specifically, diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxy...  
WO/2018/165726A1
The present invention relates to a composition comprising the alcoholic extract of the jabuticaba fruit skin (Myrciaria caulifolia) for use in the treatment of metabolic processes, such as weight loss and/or reduction of weight gain, as ...  
WO/2018/165822A1
Disclosed are sulfonamide compounds as shown in the formula (A) and the preparation method therefor, and the use of the same as urate transporter inhibitor medicines. Various compounds, and salts, hydrates or solvates thereof provided by...  
WO/2018/168898A1
The present invention pertains to a therapeutic agent against diseases involving Nav 1.7, specifically, diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme p...  
WO/2018/164186A1
The present invention provides: a nucleic acid having an activity to inhibit the expression of MASP2; a pharmaceutical composition containing the nucleic acid; and a prophylactic or therapeutic agent for autoimmune diseases including APS...  
WO/2018/161507A1
A novel low-toxicity tripterygium glycoside, being obtained by chemical processing tripterygium glycoside and adding triptriolide. The novel low-toxicity tripterygium glycoside can effectively alleviate renal pathological damage and prot...  
WO/2018/164116A1
A liposome that contains a mycolic acid and a sterol compound.  
WO/2018/165465A1
Disclosed herein are methods of treating acute kidney injury. The method can include administering a sufficient amount of a DNA origami nanostructure to a subject afflicted with AKI to increase an excretory function of said subject. In s...  
WO/2018/165132A1
Embodiments described herein generally relate to compositions and methods requiring these compositions that may act to reduce the incidence and/or reoccurrence of kidney stones and/or other pathological calcification diseases, symptoms, ...  
WO/2018/162551A1
A composition comprising resveratrol and polymyxins for use for the treatment of urinary tract infections (UTI), for use for intestinal decontamination, for use for the treatment of bacterial intestinal infectious disease, and low tract ...  
WO/2018/163192A1
An herbal extract and constituents for promoting and managing of BPH and related aging symptoms in male and addressing male health thereof using extracts from Ageratum spp.(including but not limited to Ageratum conyzoides, Ageratum coeru...  
WO/2018/163119A1
The present description relates to 1-piperidinepropionic acid or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising it, for use in the treatment of chronic fibrosing diseases.  
WO/2018/164228A1
The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition c...  
WO/2018/157190A1
The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human sub...  
WO/2018/159852A1
The purpose of the present invention is to provide a curcumin-containing solid composition which can be used as a composition for treatment or prevention of disorders or symptoms in which intracellular absorption of curcumin is beneficia...  
WO/2018/153900A1
The present invention relates to selective partial adenosine A1 receptor agonists in combination with SGLT-2 (sodium dependent glucose transporter) inhibitors, and the use thereof for the treatment and/or prophylaxis of cardiovascular an...  
WO/2018/153897A1
The present invention relates to selective partial adenosine A1 receptor agonists in combination with HCN channel blockers, and the use thereof for the treatment and/or prophylaxis of cardiovascular and renal diseases.  
WO/2018/153898A1
The present invention relates to selective partial adenosine A1 receptor agonists in combination with mineralocorticoid receptor (MR) antagonists, and the use thereof for the treatment and/or prophylaxis of cardiovascular and renal disea...  
WO/2018/153899A1
The present invention relates to selective partial adenosine A1 receptor agonists in combination with soluble guanylyl cyclase (sGC) stimulators and/or activators, and the use thereof for the treatment and/or prophylaxis of cardiovascula...  
WO/2018/153895A1
The present invention relates to selective partial adenosine A1 receptor agonists in combination with a neutral endopeptidase inhibitor and/or an angiotensin II receptor antagonist, and the use thereof for the treatment and/or prophylaxi...  
WO/2018/155398A1
The present invention addresses the problem of finding a novel medicine that has an excellent tryptophanase inhibitory effect, that suppresses deterioration of renal functions by reducing indoxyl sulfate production in blood, and that con...  
WO/2018/151239A1
The present invention addresses the problem of providing an acid-sensing ion channel inhibitor which is orally administrable. The solution of the present invention is a compound represented by formula (I) or a pharmaceutically acceptable...  
WO/2018/148856A1
The present invention provides a compound of the Formula (1) below pharmaceutically acceptable salts of the compound of Formula (1), methods of treating patients for liver disease, and processes for preparing the compounds.  
WO/2018/151815A1
Provided herein are improved processes for the preparation of a compound of Formula IX (AG- 10). Also provided herein are pharmaceutically acceptable salts of Formula (I) and Formula (lb) as well as crystalline types of Formula IX (AG- 1...  
WO/2018/148589A1
Methods and compositions are provided for detecting, diagnosing and evaluating presence of prostate cancer in a biological sample.  
WO/2018/144773A1
The present disclosure provides methods of treating diuretic resistance by administering an IL-6 antagonist to patients who require diuresis. In typical embodiments, the patient has heart failure. Optionally, the patient has elevated uri...  
WO/2018/139527A1
The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-diox o-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a pr...  
WO/2018/140456A1
Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II (1-8) plasma levels and/or increasing Angiotensin (1-7) plasma levels in a subject in need the...  
WO/2018/139599A1
Disclosed are: a compound represented by general formula (I), a pharmaceutically acceptable salt thereof or a solvate of the same; a medicinal composition comprising the same; use of the same for preventing or treating infectious disease...  
WO/2018/139404A1
As a technique for effectively treating or preventing radiation sickness associated with exposure to radiation, a therapeutic or prophylactic agent for radiation sickness associated with exposure to radiation and others are provided, whe...  
WO/2018/139527A9
The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-diox o-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a pr...  
WO/2018/139438A1
[Problem] To provide a compound useful as a cathepsin S inhibitor. [Solution] The present inventors have studied on a compound which has a cathepsin S-inhibiting activity and can be used as an active ingredient for a pharmaceutical compo...  
WO/2018/134464A1
The invention relates to adenosine A3 receptor modulators of formula (I) and to a method for preparing said compounds. Other aspects of the present invention are pharmaceutical compositions comprising an effective quantity of said compou...  
WO/2018/136636A1
The present disclosure relates to the use of hepcidin, mini-hepcidin, or a hepcidin analogue in therapeutic methods for the treatment and/or prevention of acquired iron overload or other conditions for which iron redistribution or seques...  
WO/2018/136890A1
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...  
WO/2018/136933A1
Stromal interaction molecule 1 (STIM1) is identified as a potential therapeutic target for treating diseases or conditions associated with elevated STIM1 levels. Inhibition of HDAC6 in combination with inhibition or knock down of STIM1 w...  

Matches 1 - 50 out of 46,052